PL366459A1 - Nowe związki pirydylocyjanoguanidyny - Google Patents

Nowe związki pirydylocyjanoguanidyny

Info

Publication number
PL366459A1
PL366459A1 PL02366459A PL36645902A PL366459A1 PL 366459 A1 PL366459 A1 PL 366459A1 PL 02366459 A PL02366459 A PL 02366459A PL 36645902 A PL36645902 A PL 36645902A PL 366459 A1 PL366459 A1 PL 366459A1
Authority
PL
Poland
Prior art keywords
halogen
alkylcarbonyl
aminoalkyl
formyl
alkoxycarbonyl
Prior art date
Application number
PL02366459A
Other languages
English (en)
Inventor
Fredrik Björkling
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of PL366459A1 publication Critical patent/PL366459A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02366459A 2001-05-24 2002-05-24 Nowe związki pirydylocyjanoguanidyny PL366459A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29292701P 2001-05-24 2001-05-24
US29292801P 2001-05-24 2001-05-24

Publications (1)

Publication Number Publication Date
PL366459A1 true PL366459A1 (pl) 2005-02-07

Family

ID=26967641

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02366459A PL366459A1 (pl) 2001-05-24 2002-05-24 Nowe związki pirydylocyjanoguanidyny

Country Status (18)

Country Link
US (2) US7304066B2 (pl)
EP (1) EP1397355B1 (pl)
JP (1) JP4429607B2 (pl)
KR (1) KR20030097897A (pl)
CN (1) CN1247570C (pl)
AT (1) ATE442362T1 (pl)
BR (1) BR0209930A (pl)
CA (1) CA2447021C (pl)
CZ (1) CZ20033190A3 (pl)
DE (1) DE60233656D1 (pl)
ES (1) ES2328799T3 (pl)
HK (1) HK1066216A1 (pl)
HU (1) HUP0400021A3 (pl)
IL (1) IL158574A0 (pl)
MX (1) MXPA03010669A (pl)
PL (1) PL366459A1 (pl)
RU (1) RU2292344C2 (pl)
WO (1) WO2002094813A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
CN1918131B (zh) * 2004-02-05 2011-05-04 前体生物药物股份公司 谷氨酰胺酰基环化酶抑制剂
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
JP5189367B2 (ja) * 2004-12-22 2013-04-24 レオ ファーマ アクティーゼルスカブ 新規シアノグアニジン化合物
WO2007005534A2 (en) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
RU2011111728A (ru) 2008-08-29 2012-10-10 Топотаргет А/С (Dk) Новые производные мочевины и тиомочевины
CA2751495C (en) * 2009-02-06 2013-08-20 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
WO2011006988A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
US8604065B2 (en) 2010-02-04 2013-12-10 Hesheng Zhang Pyridyl cyanoguanidine derivatives
WO2011095027A1 (zh) * 2010-02-04 2011-08-11 天津和美生物技术有限公司 吡啶基氰基胍衍生物
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
EP2611778B1 (en) * 2010-09-03 2015-08-05 Forma TM, LLC. Guanidine compounds and compositions for the inhibition of nampt
JP2013540781A (ja) 2010-10-26 2013-11-07 ティエンジン ホーメイ バイオ−テック カンパニー， リミテッド Ｎ−（６−（４−クロロフェノキシ）ヘキシル）−ｎ’−シアノ−ｎ’’−（４−ピリジル）グアニジンの結晶多形とその製造及び使用
PT2649048T (pt) * 2010-12-09 2016-07-13 Radikal Therapeutics Inc Derivados de nitróxido multifuncionais e usos dos mesmos
IL289300B2 (en) * 2012-04-13 2024-05-01 Epizyme Inc Combined treatment for cancer
KR101656663B1 (ko) 2015-07-27 2016-09-13 충남대학교산학협력단 암 예방 및 치료용 조성물
PT3837256T (pt) 2018-08-17 2023-05-23 Novartis Ag Compostos e composições de ureia como inibidores de smarca2/brm-atpase
CN110734405A (zh) * 2019-11-11 2020-01-31 华东数字医学工程研究院 一种n-(6-氨己基)-n’-甲基-2,2’-联咪唑的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696140A (en) * 1992-09-15 1997-12-09 Leo Pharmaceutical Products Ltd. N-cyano-N'-pyridylguanidines as serotonin antagonists
GB9219472D0 (en) * 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9711123D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711122D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711119D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US7129043B1 (en) * 1998-10-22 2006-10-31 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
WO2000061561A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU4076500A (en) 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds
ES2292462T3 (es) 1999-08-03 2008-03-16 Abbott Laboratories Agentes abridores de los canales del potasio.
US6645968B2 (en) 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers

Also Published As

Publication number Publication date
CA2447021A1 (en) 2002-11-28
CN1247570C (zh) 2006-03-29
RU2003137007A (ru) 2005-04-20
CA2447021C (en) 2010-08-10
KR20030097897A (ko) 2003-12-31
ES2328799T3 (es) 2009-11-18
JP4429607B2 (ja) 2010-03-10
US7304066B2 (en) 2007-12-04
IL158574A0 (en) 2004-05-12
US20040220408A1 (en) 2004-11-04
EP1397355A1 (en) 2004-03-17
DE60233656D1 (de) 2009-10-22
MXPA03010669A (es) 2004-07-01
US20080090842A1 (en) 2008-04-17
BR0209930A (pt) 2004-03-30
ATE442362T1 (de) 2009-09-15
HK1066216A1 (en) 2005-03-18
CN1509283A (zh) 2004-06-30
CZ20033190A3 (cs) 2004-06-16
JP2005508859A (ja) 2005-04-07
HUP0400021A3 (en) 2008-03-28
WO2002094813A1 (en) 2002-11-28
EP1397355B1 (en) 2009-09-09
US7807682B2 (en) 2010-10-05
RU2292344C2 (ru) 2007-01-27
HUP0400021A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
IL158574A0 (en) Novel pyridyl cyanoguanidine compounds
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
MXPA05013142A (es) Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
HK1086256A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
HK1080470A1 (en) Heterocyclic compounds
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
ATE302775T1 (de) Carbolinderivate
MY130697A (en) 4-trifluoromethylpyrazolyl-substituted pyridines and pyrimidines
AU2002249890A1 (en) Carboline derivatives
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
AU2002213421A1 (en) Condensed pyridoindole derivatives
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
MXPA03002909A (es) Compuestos quimicos.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
IL161842A0 (en) 2-Amino-4-heteroarylethyl-thiazoline derivatives and their use as inhibitors of inducible no-synthase
PL1791811T3 (pl) Pochodne aminoalkoholi
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)